AU2001257505A1 - Hepatitis c virus helicase crystals, crystallographic structure and methods - Google Patents

Hepatitis c virus helicase crystals, crystallographic structure and methods

Info

Publication number
AU2001257505A1
AU2001257505A1 AU2001257505A AU5750501A AU2001257505A1 AU 2001257505 A1 AU2001257505 A1 AU 2001257505A1 AU 2001257505 A AU2001257505 A AU 2001257505A AU 5750501 A AU5750501 A AU 5750501A AU 2001257505 A1 AU2001257505 A1 AU 2001257505A1
Authority
AU
Australia
Prior art keywords
hepatitis
crystals
methods
crystallographic structure
virus helicase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001257505A
Other languages
English (en)
Inventor
Eric Baldwin
Barry C. Finzel
Melissa S. Harris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia and Upjohn Co
Publication of AU2001257505A1 publication Critical patent/AU2001257505A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
    • G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Theoretical Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Analytical Chemistry (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2001257505A 2000-05-03 2001-05-02 Hepatitis c virus helicase crystals, crystallographic structure and methods Abandoned AU2001257505A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20159800P 2000-05-03 2000-05-03
US60/201,598 2000-05-03
PCT/US2001/014233 WO2001088113A2 (fr) 2000-05-03 2001-05-02 Cristaux d'helicase du virus de l'hepatite c, structure cristallographique and procedes

Publications (1)

Publication Number Publication Date
AU2001257505A1 true AU2001257505A1 (en) 2001-11-26

Family

ID=22746483

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001257505A Abandoned AU2001257505A1 (en) 2000-05-03 2001-05-02 Hepatitis c virus helicase crystals, crystallographic structure and methods

Country Status (3)

Country Link
US (1) US20040126809A9 (fr)
AU (1) AU2001257505A1 (fr)
WO (1) WO2001088113A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6950757B2 (en) 2001-04-11 2005-09-27 Emerald Biostructures, Inc. Screening methods for identifying ligands
JP4416150B2 (ja) * 2002-10-15 2010-02-17 大日本印刷株式会社 立体彩紋
EP1627323A4 (fr) * 2003-05-06 2008-04-09 New Century Pharmaceuticals Sites de fixation sur l'albumine pour l'evaluation d'interactions medicamenteuses ou la mise au point de medicaments en fonction de leur proprietes de liaison a l'albumine
US20070043509A1 (en) * 2003-11-03 2007-02-22 Carter Daniel C Albumin binding sites for evaluating drug interactions and methods of evaluating or designing drugs based on their albumin binding properties
CN103184264B (zh) * 2011-12-29 2017-05-17 天津市国际生物医药联合研究院 从红果小檗粗提物中筛选出的1型艾滋病病毒蛋白酶抑制剂及其应用
CN110361407B (zh) * 2019-07-23 2020-07-28 中国科学院生物物理研究所 一种用于蛋白质晶体原位x-射线衍射的装置

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6183121B1 (en) * 1997-08-14 2001-02-06 Vertex Pharmaceuticals Inc. Hepatitis C virus helicase crystals and coordinates that define helicase binding pockets

Also Published As

Publication number Publication date
WO2001088113A3 (fr) 2003-01-30
US20030165984A1 (en) 2003-09-04
WO2001088113A2 (fr) 2001-11-22
US20040126809A9 (en) 2004-07-01

Similar Documents

Publication Publication Date Title
EP1292603B8 (fr) Methodes et compositions permettant de traiter le virus de l'hepatite c
AU2001282528A1 (en) Compounds having anti-hepatitis c virus effect
AU5285899A (en) Anti hepatitis c virus antibody and uses thereof
AU2002353790A1 (en) Syringe and reconstitution syringe
AU2001280906A1 (en) Method for inoculating infected email
AU2002210450A1 (en) Maintaining virus detection software
AU2002211949A1 (en) Particulate trap
AU2002230764A1 (en) Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors
AU2001245356A1 (en) Inhibitors of hepatitis c virus ns3 protease
AU2001297896A1 (en) Mutant proteins, high potency inhibitory antibodies and fimch crystal structure
AUPQ912000A0 (en) Improved virus like particles
AU1324300A (en) Pentacyclic compounds useful as inhibitors of hepatitis c virus ns3 helicase
GB0017720D0 (en) Modified virus
AU2001238501A1 (en) Selective destruction of cells infected with human immunodeficiency virus
AU2001246331A1 (en) Hepatitis b virus (hbv) antigenic polypeptide-heat shock protein complex and use thereof
AU2001267645A1 (en) Cyclic urea compounds and preparation thereof
IL143798A0 (en) Hepatitis c virus ns3 protease
AU2001240018A1 (en) Adeno-associated viral compositions and methods
AU2001257505A1 (en) Hepatitis c virus helicase crystals, crystallographic structure and methods
AU4529401A (en) Aids ancestral viruses and vaccines
AU2002257890A1 (en) Method for replicating the hepatitis C virus
AU2003301865A1 (en) Epitopes of hepatitis c virus
AU3184701A (en) Mutated hepatitis B virus, its nucleic and protein constituents and uses thereof
AU5647501A (en) Crystallography methods
AU2003230790A1 (en) Hepatitis c virus sub-genomic replicons